Inflammatory ocular adverse events with the use of oral bisphosphonates: a retrospective cohort study | CMAJ

Article Figures & Tables

Tables

View popup

Table 1:

Characteristics of included patients, stratified by use of oral bisphosphonate

Characteristic	No. (%)^* of patients
Characteristic	First-time bisphosphonate use n = 10 827	No bisphosphonate use n = 923 320
Scleritis	392 (3.6)	16 305 (1.8)
Uveitis	185 (1.7)	9 320 (1.0)
Age cohort entry, yr, mean (SD)	68.7 (12.6)	51.3 (22.3)
Male	2 414 (22.3)	446 889 (48.4)
Follow-up, yr, mean (SD)	5.9 (1.9)	4.9 (2.2)
Sulfa-containing drugs	822 (7.6)	48 013 (5.2)
Comorbidity
Ankylosing spondylitis	32 (0.3)	1 847 (0.2)
Psoriasis	173 (1.6)	13 850 (1.5)
Inflammatory bowel disease	108 (1.0)	6 463 (0.7)
Rheumatoid arthritis	476 (4.4)	18 466 (2.0)
Diabetes	1 602 (14.8)	138 498 (15.1)
Systemic lupus erythematosus	152 (1.4)	5 539 (0.6)
Sarcoidosis	22 (0.2)	923 (0.1)
Multiple sclerosis	433 (0.4)	3 693 (0.4)

Note: SD = standard deviation.
↵* Unless otherwise stated.

View popup
Table 2:
Crude, adjusted and propensity-adjusted rate ratios for the risk of uveitis and scleritis among first-time users of oral bisphosphonate
Outcome Crude RR Adjusted^* RR Propensity-adjusted^* RR
Uveitis 1.54 (1.33–1.78) 1.45 (1.25–1.68) 1.50 (1.29–1.73)
Scleritis 1.85 (1.68–2.05) 1.51 (1.34–1.68) 1.53 (1.39–1.70)
Note: RR = rate ratio.
↵* Adjusted for age at index, sex, calendar time, use of sulfa-containing drugs, and comorbidities (ankylosing spondylitis, psoriasis, inflammatory bowel disease, rheumatoid arthritis, diabetes, systemic lupus erythematosus, sarcoidosis, multiple sclerosis).

In this issue

Article tools

Respond to this article

Print

Request Permissions

Related Articles

Cited By...

Google Scholar

More in this TOC Section

Show more Research

Similar Articles

Collections

Topics
- Drugs: adverse reactions
- Ophthalmology